Skip to main content
SpringerLink
Log in

The Discovery and Characterisation of Tumour Endothelial Markers

  • Chapter
  • First Online:
Vascular Disruptive Agents for the Treatment of Cancer

  • 350 Accesses

Abstract

One avenue towards the development of more selective anti-cancer drugs consists in the targeted delivery of bioactive molecules (drugs, cytokines, ­procoagulant factors, photosensitizers, radionuclides, etc.) to the tumor environment by means of binding molecules (e.g., human antibodies) specific to tumor-associated markers. In this context, the targeted delivery of therapeutic agents to newly-formed blood vessels (“vascular targeting”) is particularly attractive, because of the dependence of tumors on new blood vessels to sustain growth and invasion, and because of the accessibility of neo-vascular structures for therapeutic agents injected intravenously.

This chapter reviews modern methodologies for the discovery of vascular tumor markers for pharmacodelivery applications and outlines the key properties of some of the best characterized targets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Armstrong LJ, Heath VL, Sanderson S, Kaur S, Beesley JFJ, Herbert JMJ, Legg JA, Poulsom R and Bicknell R (2008) ECSM2, an endothelial specific filamin A binding protein that mediates chemotaxis. Arterio Thromb Vasc Biol, 28, 1640–1646.

    CAS  Google Scholar 

  • Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A (2001) Lack of specificity of endoglin for tumor blood vessels. Int J Cancer, 94, 579–585.

    PubMed  CAS  Google Scholar 

  • Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol, 23, 4591–4601.

    PubMed  CAS  Google Scholar 

  • Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM (2005) Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res, 11, 7053s–7063s.

    PubMed  CAS  Google Scholar 

  • Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C, Dreischauck J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE (2009) Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood, 113, 5019–5027.

    PubMed  CAS  Google Scholar 

  • Birchler M, Viti F, Zardi L, Spiess B, Neri D (1999) Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived recombinant antibody. Nat Biotechnol, 17, 984–988.

    PubMed  CAS  Google Scholar 

  • Birchler MT, Milisavlijevic, Pfaltz DM, Neri D, Odermatt B, Schmid S, Stoeckli SJ (2003) Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope, 113, 1231–1237.

    PubMed  CAS  Google Scholar 

  • Borgia B, Rösli C, Fugmann T, Neri D, Giavazzi R (2010) Accessible markers of liver metastasis revealed by mass spectrometric analysis of vascular structures biotinylated by perfusion of tumor-bearing mice. Cancer Res, 70, 309–318.

    PubMed  CAS  Google Scholar 

  • Borsi L, Balza E, Gaggero B, Allemanni G and Zardi L (1995) The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem, 270, 6243–6245.

    PubMed  CAS  Google Scholar 

  • Borsi L, Castellani P, Allemanni G, Neri D, Zardi L (1998) Preparation of phage antibodies to the ED-A domain of human fibronectin, mediator of hepatic fibrogenesis. Exp Cell Res, 240, 244–251.

    PubMed  CAS  Google Scholar 

  • Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer, 102, 75–85.

    PubMed  CAS  Google Scholar 

  • Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNF{alpha| to tumor blood vessels. Blood, 102, 4384–4392.

    PubMed  CAS  Google Scholar 

  • Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res, 12, 3200–3208.

    PubMed  CAS  Google Scholar 

  • Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R (2000) Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer, 36, 675–681.

    PubMed  CAS  Google Scholar 

  • Brooks PC, Clark RA and Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 264, 569–571.

    PubMed  CAS  Google Scholar 

  • Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH and Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 96, 1815–1822.

    PubMed  CAS  Google Scholar 

  • Burrows FJ, Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA, 90, 8996–9000.

    PubMed  CAS  Google Scholar 

  • Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King, SW, Letarte M, Vitetta ES, Thorpe PE (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res, 1, 1623–1634.

    PubMed  CAS  Google Scholar 

  • Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG (1989) A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol, 108, 1139–1148.

    PubMed  CAS  Google Scholar 

  • Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer, 68, 397–405.

    PubMed  CAS  Google Scholar 

  • Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo’ G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L (1999) Identification of a glioblastoma associated TN-C isoform by a high affinity recombinant antibody. Am J Pathol, 154, 1345–1352.

    PubMed  CAS  Google Scholar 

  • Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D and Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood, 99, 1659–1665.

    PubMed  Google Scholar 

  • Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler K, St Croix B (2001) Cell surface tumour endothelial markers are conserved in mice and humans. Cancer Res, 63, 5866–73.

    Google Scholar 

  • Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol, 6, 343–357.

    PubMed  CAS  Google Scholar 

  • Carter PJ, Senter P (2008) Antibody-drug conjugates for cancer therapy. Cancer J, 14, 154–169.

    PubMed  CAS  Google Scholar 

  • Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer, 59, 612–618.

    PubMed  CAS  Google Scholar 

  • Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale GL, Neri D, Zardi L (2002) Differentiation between high and low grade astrocytoma using a human recombinant antibody to the ED-B domain of fibronectin. Am J Pathol, 161, 1695–1700.

    PubMed  CAS  Google Scholar 

  • Castronovo V, Waltregny D, Kishel P, Elia G, Rösli C, Rybak J, Neri D (2006) A chemical proteomic approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics, 5, 2083–2091.

    PubMed  CAS  Google Scholar 

  • Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res, 5, 2674–2681.

    PubMed  CAS  Google Scholar 

  • Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs, 7, 522–528.

    PubMed  CAS  Google Scholar 

  • Conrotto P, Rösli C, Rybak JN, Kishel P, Waltregny D, Neri D, Castronovo V (2008) Identification of novel tumor-associated and accessible antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer, 123, 2856–2864.

    PubMed  CAS  Google Scholar 

  • Cooke SP, Boxer GM, Lawrence L, Pedley RB, Spencer DI, Begent RH, Chester KA. (2001) A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res, 61, 3653–3659.

    PubMed  CAS  Google Scholar 

  • Corti A, Curnis F, Arap W, Pasqualini R (2008) The neovasculature homing motif NGR: more than meets the eye. Blood, 112, 2628–2635.

    PubMed  CAS  Google Scholar 

  • Dallas NA Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res, 14(7), 1931–1937.

    Google Scholar 

  • Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leukemia Res, 33, 1718–1722.

    CAS  Google Scholar 

  • Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev, 9, 267–282.

    PubMed  CAS  Google Scholar 

  • Driemel O, Kosmehl H, Rosenhahn J, Berndt A, Reichert TE, Zardi L, Dahse R (2007) Expression analysis of extracellular matrix components in brush biopsies of oral lesions. Anticancer Res, 27, 1565–1570.

    PubMed  CAS  Google Scholar 

  • Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D (2005) An engineered vascular-targeting antibody-interferon gamma fusion protein for cancer therapy. Int J Cancer, 116, 304–313.

    PubMed  CAS  Google Scholar 

  • Essler M and Ruoslahti E (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A, 99, 2252–2257.

    PubMed  CAS  Google Scholar 

  • Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, Kosmehl H, Zardi L, Neri D, Neri P (2006) Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer, 118, 1805–1813.

    PubMed  CAS  Google Scholar 

  • Fernando S, Fletcher BS (2009) Targeting tumor endothelial marker 8 in the tumor vasculature of colorectal carcinomas in mice. Cancer Res, 69, 5126–5132.

    PubMed  CAS  Google Scholar 

  • Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl 1), 2–10.

    PubMed  CAS  Google Scholar 

  • Ferrara C, Stuart F, Sondermann P, Brünker P, Umana P (2006) The carbohydrate at FcgammaRIIIa Asn 162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem, 281, 5032–5036.

    PubMed  CAS  Google Scholar 

  • Folkman J (1990) What is the evidence that tumours are angiogenesis dependant? J Natl Cancer Inst, 82, 4–6.

    PubMed  CAS  Google Scholar 

  • Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M (2000) Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res, 6, 2037–2043.

    PubMed  CAS  Google Scholar 

  • Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, Toy K, Winer J, Draksharapu A, Peale F, Wu FTD, Williams PM (2002) In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics, 10, 13–20.

    PubMed  CAS  Google Scholar 

  • Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M (2008) Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics, 9, 201.

    PubMed  Google Scholar 

  • Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol, 20, 264–269.

    PubMed  CAS  Google Scholar 

  • Heinis C, Alessi P, Neri D (2004) Engineering a thermostable human prolyl endopeptidase for antibody directed enzyme prodrug therapy (ADEPT). Biochemistry, 43, 6293–6303.

    PubMed  CAS  Google Scholar 

  • Herbert JM, Stekel D, Sanderson S, Heath VL, Bicknell R (2008) A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics, 9, 153–174.

    PubMed  Google Scholar 

  • Ho M, Yang E, Matcuk G, Deng D, Sampas N, Tsalenko A, Tabibiazar R, Zhang Y, Chen M, Talbi S, Ho YD, Wang J, Tsao PS, Ben-Dor A, Yakhini Z, Bruhn L and Quatermous T (2003) Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol Genomics, 13, 249–62.

    PubMed  CAS  Google Scholar 

  • Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275, 547–550.

    PubMed  CAS  Google Scholar 

  • Huang X, Bennett M, Thorpe PE (2005) A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res, 65, 4408–4416.

    PubMed  CAS  Google Scholar 

  • Huminiecki L, Bicknell R (2000) In silico cloning of novel endothelial-specific genes. Genome Res, 10, 1796–1806.

    PubMed  CAS  Google Scholar 

  • Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics, 79, 547–552.

    PubMed  CAS  Google Scholar 

  • Jennewein M, Lewis MA, Zhao D, Tsyganov E, Slavine N, He J, Watkins L, Kodibagkar VD, O’Kelly S, Kulkarni P, Antich PP, Hermanne A, Rösch F, Mason RP, Thorpe PE (2008) Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res, 14, 1377–1385.

    PubMed  CAS  Google Scholar 

  • Kim S, Bell K, Mousa SA, Varner JA (2000a) Regulation of angiogenesis in vivo by ligation of integrin alpha5 beta 1 with the central cell-binding domain of fibronectin. Am J Pathol, 156, 1345–1362.

    PubMed  CAS  Google Scholar 

  • Kim S, Harris M and Varner JA (2000b) Regulation of integrin alpha v beta 3 mediated endothelial cell migration and angiogenesis by integrin alpha 5 beta 1 and protein kinase A. J Biol Chem, 275, 33920–33928.

    PubMed  CAS  Google Scholar 

  • Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA (2007) Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res, 13, 323–330.

    PubMed  CAS  Google Scholar 

  • Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH (2007) Compressing drug development timelines using Phase “0” clinical trials. Nat Rev Drug Disc, 7, 131–139.

    CAS  Google Scholar 

  • Legg JA, Herbert JMJ, Clissold P, Bicknell R (2008) Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis 11, 13–21.

    PubMed  Google Scholar 

  • Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res, 57, 3629–3634.

    PubMed  CAS  Google Scholar 

  • Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, Thorpe PE (2006) Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem, 281, 29863–29871.

    PubMed  CAS  Google Scholar 

  • Ma F, Zhang D, Yang H, Sun H, Wu W, Gan Y, Balducci J, Wei Y, Zhao X, Huang Y (2009) Endothelial cell-specific molecule 2 (ECSM2) modulates actin remodeling and epidermal growth factor receptor signaling. Genes to Cell, 14, 281–293.

    PubMed  CAS  Google Scholar 

  • MacFayden JR, Haworth O, Roberston D, Hardie D, Webster M-T, Morris HR, Panico M, Sutton-Smith M, Dell A, van der Greer P, Wienke D, Buckley Cd, Isacke CM (2005) Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett, 579, 2569–2575.

    Google Scholar 

  • Mårlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) The antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res, 14, 6515–6524.

    PubMed  Google Scholar 

  • Max R, Gerritsen RR Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM (1997) Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer, 71, 320–324.

    PubMed  CAS  Google Scholar 

  • Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol, 25, 540–547.

    PubMed  CAS  Google Scholar 

  • Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O’Donoghue JA, Nacca A, Smith-Jones P, Schwartz L, Slovin S, Finn R, Larson S, Scher HI (2007) Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res, 13, 2707–2713.

    PubMed  CAS  Google Scholar 

  • Murphy K, Travers P, Walport M (2008) Janeway’s Immunobiology, 7th Ed., Garland Science, New York and London.

    Google Scholar 

  • Mutuberria R, Satijn S, Huijbers A, Van Der Linden E, Lichtenbeld H, Chames P, Arends JW, Hoogenboom HR (2004) Isolation of human antibodies to tumor-associated endothelial markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods, 287, 31–47.

    PubMed  CAS  Google Scholar 

  • Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH (2003) Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol, 170 (Pt 2) S84–S89.

    PubMed  Google Scholar 

  • Neri D, Bicknell R (2005) Vascular tumour targeting. Nat Rev Cancer, 5, 436–446.

    Google Scholar 

  • Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol, 15, 1271–1275.

    PubMed  CAS  Google Scholar 

  • Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumours in mice, Cancer Res, 61, 711–716.

    PubMed  CAS  Google Scholar 

  • Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science, 310, 1510–1512.

    PubMed  CAS  Google Scholar 

  • Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature, 429, 629–635.

    PubMed  CAS  Google Scholar 

  • Pedretti M, Soltermann A, Arni S, Weder W, Neri D, Hillinger S (2009) Comparative ­immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer, 64, 28–33

    PubMed  Google Scholar 

  • Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D (1998) Design and use of a phage-display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem, 273, 21769–21776.

    PubMed  CAS  Google Scholar 

  • Ran S, Downes A, Thorpe PE (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res, 62, 6132–6140.

    PubMed  CAS  Google Scholar 

  • Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE (2005) Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res, 11, 1551–1562.

    PubMed  CAS  Google Scholar 

  • Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol, 24, 115–122.

    PubMed  CAS  Google Scholar 

  • Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A, 89, 10832–10836.

    PubMed  CAS  Google Scholar 

  • Rösli C, Mumprecht VD, Neri D, Detmar M (2008) Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J, 22, 1933–1944.

    Google Scholar 

  • Roy S, Patel D, Khanna S, Gordillo GM, Biswas S, Friedman A, Sen CK (2007) Transcriptome-wide analysis of blood vessels laser captured from human skin and chronic wound edge tissue. Proc Natl Acad Sci U S A, 104, 14472–14477.

    PubMed  CAS  Google Scholar 

  • Ruan W, Sassoon A, An F, Simko JP, Liu B (2006) Identification of clinically significant tumour antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics, 5(12), 2364–2373.

    PubMed  CAS  Google Scholar 

  • Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods, 2, 291–298.

    CAS  Google Scholar 

  • Rybak JN, Roesli C, Kaspar M, Villa A, Neri D (2007) The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res, 67, 10948–10957.

    PubMed  CAS  Google Scholar 

  • Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res, 9, 571–579.

    PubMed  CAS  Google Scholar 

  • Sauer A, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD (2009) Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood, 113, 2265–2274.

    PubMed  CAS  Google Scholar 

  • Schliemann C, Neri D (2007) Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta, 1776, 175–192.

    PubMed  CAS  Google Scholar 

  • Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood, 113, 2275–2283.

    PubMed  CAS  Google Scholar 

  • Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov, 5, 147–159.

    PubMed  CAS  Google Scholar 

  • Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell, 11, 539–554.

    PubMed  CAS  Google Scholar 

  • Seth P, Lin Y, Hanai J, Shivalingappa V, Duyao MP, Sukhatme VP (2005) Magic roundabout, a tumour endothelial marker: expression and signaling. Biochem Biophys Res Commun, 332, 533–541.

    PubMed  CAS  Google Scholar 

  • Sharkey RM, Goldenberg DM (2008) Novel radiopharmaceuticals for cancer imaging and therapy. Curr Opin Investig Drugs, 9, 1302–1316.

    PubMed  CAS  Google Scholar 

  • Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH, Chester KA (2005) Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res, 11, 814–825.

    PubMed  CAS  Google Scholar 

  • Sheldon H, Andre M, Legg JA, Heal P, Herbert JM, Sainson R, Sharma AS, Kitajewski JK, Heath VL, Bicknell R (2009) Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation promoting factors. FASEB J, 23, 513–522.

    PubMed  CAS  Google Scholar 

  • Silacci M, Brack SS, Spaeth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel, 19, 471–478.

    PubMed  CAS  Google Scholar 

  • Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res, 3, 81–85.

    PubMed  CAS  Google Scholar 

  • Soares MM, King SW, Thorpe PE (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med, 14, 1357–1362.

    PubMed  CAS  Google Scholar 

  • St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes expressed in human tumor endothelium. Science, 289, 1197–1202.

    PubMed  CAS  Google Scholar 

  • Stollman TH, Scheer MGW, Leenders WPJ, Verrijp CN, Soede AC, Oyen WJG, Ruers TJM, Boerman OC (2008) Specific imaging of VEFG-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer, 122, 2310–2314.

    PubMed  CAS  Google Scholar 

  • Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D, Barker J, Bicknell R (2003) EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem, 278, 47079–47088.

    PubMed  CAS  Google Scholar 

  • Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood, 94, 192–198.

    PubMed  CAS  Google Scholar 

  • Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA (2006) Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med, 47, 1127–1135.

    PubMed  CAS  Google Scholar 

  • Tijink BM, Perk LR, Budde M, van Walsum MS, Visser GWM, Klet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GAMS (2009) 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging, 36, 1235–1244.

    PubMed  Google Scholar 

  • Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak J, Rösli C, Borsi L, Zardi L and Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively-spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer, 122, 2405–2413.

    PubMed  CAS  Google Scholar 

  • Viti F, Tarli L, Giovannoni L, Zardi L, Neri D (1999) Binding affinity and valence determine the tumour targeting performance of anti-angiogenesis antibodies. Cancer Res, 59, 347–352.

    PubMed  CAS  Google Scholar 

  • Walsh G (2006) Biopharmaceuticals benchmark. Nat Biotechnol, 24, 769–776.

    PubMed  CAS  Google Scholar 

  • Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer, 54, 363–370.

    PubMed  CAS  Google Scholar 

  • Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol, 12, 433–455.

    PubMed  CAS  Google Scholar 

  • Wyder L, Vitaliti A, Schneider H, Hebbard LW, Moritz DR, Wittmer M, Ajmo M, Klemenz R (2000) Increased expression of H/T-cadherin in tumor-penetrating blood vessels. Cancer Res, 60, 4682–4688.

    PubMed  CAS  Google Scholar 

  • Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Freidman HS, McLendon RE, Wong TZ and Bigner DD (2008) Clinical experience with alpha particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med, 49, 30–38.

    PubMed  CAS  Google Scholar 

  • Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J, 6, 2337–2342.

    PubMed  CAS  Google Scholar 

  • Zhang HT, Gorn M, Smith K, Graham AP, Lau KK and Bicknell R (1999) Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis, 3, 211–219.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry and Applied Biosciences, ETH Zurich, Wolfgang-Pauli-Str. 10, CH-8093, Zurich, Switzerland

    Dario Neri

Authors
  1. Dario Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roy Bicknell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dario Neri .

Editor information

Editors and Affiliations

  1. Cancer Institute, University College London, Huntlely St. 72, London, WC1E 6BT, United Kingdom

    Tim Meyer

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Neri, D., Bicknell, R. (2010). The Discovery and Characterisation of Tumour Endothelial Markers. In: Meyer, T. (eds) Vascular Disruptive Agents for the Treatment of Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6609-4_2

Download citation

Publish with us

Policies and ethics

Search

Navigation